GS
Grifols, S.A. Stock: price and insider trades · Spain
Grifols, S.A.: what insiders have been doing
Grifols, S.A. has a thin disclosure history in our data. New filings will appear here as soon as they are published. This summary is built from CNMV disclosures alone and does not predict where the share price will go.
Insider Decl.
n/a
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Grifols, S.A. Buy (bullish), based on 12 analysts. Average price target: €14.76.
Fundamental score
Ranked 11,229 of 26,911 companies
55.8
score / 100
Value67
Quality45
FCF yld9.0%
Earn yld5.8%
EV/EBITDA10.0x
ROE6.9%
Gross mgn38%
Net mgn5.3%
Debt/EBITDA5.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€10.18
Analyst consensus
12 analystsBuy
€9.00Target €14.76(+45%)€23.00
Income statement
Revenue€7.5B
Gross profit€2.9B38% margin
EBITDA€1.6B22% margin
Net income€402.0M6.1% margin
Valuation
PER (trailing)15.4x
PER (forward)9.0x
P/Book1.2x
Beta1.19
Balance sheet & cash
Market cap€6.9B
Total debt€9.6B
Free Cash Flow€624.0M
Debt / Equity117%
Profitability & ownership
ROE6.9%
ROA4.2%
% insiders31.2%
% institutions38.2%
Declarations0 total
No declarations found
0 of 0 declarations
About Grifols, S.A.
Grifols, S.A. is a Spanish company specializing in the healthcare and pharmaceutical sector, known for its plasma-derived products. It is listed on the Spanish stock market, XMAD.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
